ORBi: Detailled Reference

Article (Scientific journals)

Precision medicine: The future in diabetes care?

Scheen, André

2016 • In Diabetes Research and Clinical Practice, 117, p. 12-21

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/200447

DOI
10.1016/j.diabres.2016.04.033

PubMed
27329017

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2013 DRCP precision medicine.pdf

Publisher postprint (455.75 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Patient-centred therapy; Personalized medicine; Pharmacogenetics; Pharmacogenomics; Precision medicine; Type 2 diabetes

Abstract :

[en] Personalized medicine aims at better targeting therapeutic intervention to the individual to maximize benefit and minimize harm. Type 2 diabetes (T2D) is a heterogeneous disease from a genetic, pathophysiological and clinical point of view. Thus, the response to any antidiabetic medication may considerably vary between individuals. Numerous glucose-lowering agents, with different mechanisms of action, have been developed, a diversified armamentarium that offers the possibility of a patient-centred therapeutic approach. In the current clinical practice, a personalized approach is only based upon phenotype, taking into account patient and disease individual characteristics. If this approach may help increase both efficacy and safety outcomes, there remains considerable room for improvement. In recent years, many efforts were taken to identify genetic and genotype SNP's (Single Nucleotide Polymorphism's) variants that influence the pharmacokinetics, pharmacodynamics, and ultimately the therapeutic response of oral glucose-lowering drugs. This approach mainly concerns metformin, sulphonylureas, meglitinides and thiazolidinediones, with only scarce data concerning gliptins and gliflozins yet. However, the contribution of pharmacogenetics and pharmacogenomics to personalized therapy still needs to mature greatly before routine clinical implementation is possible. This review discusses both opportunities and challenges of precision medicine and how this new paradigm may lead to a better individualized treatment of T2D.

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège > Département des sciences cliniques > Diabétologie, nutrition et maladie métaboliques

Language :

English

Title :

Precision medicine: The future in diabetes care?

Publication date :

2016

Journal title :

Diabetes Research and Clinical Practice

ISSN :

0168-8227

eISSN :

1872-8227

Publisher :

Elsevier, Amsterdam, Netherlands

Volume :

117

Pages :

12-21

Peer reviewed :

Peer Reviewed verified by ORBi

Commentary :

Copyright (c) 2016. Published by Elsevier Ireland Ltd.

Available on ORBi :

since 18 July 2016

Statistics

Number of views

67 (2 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

36

Scopus citations^®
without self-citations

26

OpenCitations

33

Bibliography

Cantrell, R.A., Alatorre, C.I., Davis, E.J., Zarotsky, V., Le Nestour, E., Carter, G.C., et al. A review of treatment response in type 2 diabetes: assessing the role of patient heterogeneity. Diabetes Obes Metab 12 (2010), 845–857.
Leslie, R.D., Palmer, J., Schloot, N.C., Lernmark, A., Diabetes at the crossroads: relevance of disease classification to pathophysiology and treatment. Diabetologia 59 (2016), 13–20.
Kaul, N., Ali, S., Genes, genetics, and environment in type 2 diabetes: implication in personalized medicine. DNA Cell Biol 35 (2016), 1–12.
Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., et al. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American diabetes association and the European association for the study of diabetes. Diabetologia 58 (2015), 429–442.
Garber, A.J., Abrahamson, M.J., Barzilay, J.I., Blonde, L., Bloomgarden, Z.T., Bush, M.A., et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm – 2016 executive summary. Endocr Pract 22 (2016), 84–113.
Raz, I., Riddle, M.C., Rosenstock, J., Buse, J.B., Inzucchi, S.E., Home, P.D., et al. Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors’ Expert Forum. Diabetes Care 36 (2013), 1779–1788.
Scheen, A.J., Lefebvre, P.J., Oral antidiabetic agents. A guide to selection. Drugs 55 (1998), 225–236.
Kleinberger, J.W., Pollin, T.I., Personalized medicine in diabetes mellitus: current opportunities and future prospects. Ann N Y Acad Sci 1346 (2015), 45–56.
Smith, R.J., Nathan, D.M., Arslanian, S.A., Groop, L., Rizza, R.A., Rotter, J.I., Individualizing therapies in type 2 diabetes mellitus based on patient characteristics: what we know and what we need to know. J Clin Endocrinol Metab 95 (2010), 1566–1574.
Maruthur, N.M., Gribble, M.O., Bennett, W.L., Bolen, S., Wilson, L.M., Balakrishnan, P., et al. The pharmacogenetics of type 2 diabetes: a systematic review. Diabetes Care 37 (2014), 876–886.
Scheen, A.J., A review of gliptins for 2014. Exp Opin Pharmacother 16 (2015), 43–62.
Scheen, A.J., Pharmacodynamics, efficacy and safety of sodium–glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus. Drugs 75 (2015), 33–59.
Del Prato, S., LaSalle, J., Matthaei, S., Bailey, C.J., Global Partnership for Effective Diabetes M, Tailoring treatment to the individual in type 2 diabetes practical guidance from the global partnership for effective diabetes management. Int J Clin Pract 64 (2010), 295–304.
Bailey, C.J., Aschner, P., Del Prato, S., LaSalle, J., Ji, L., Matthaei, S., et al. Individualized glycaemic targets and pharmacotherapy in type 2 diabetes. Diab Vasc Dis Res 10 (2013), 397–409.
Ceriello, A., Gallo, M., Candido, R., De Micheli, A., Esposito, K., Gentile, S., et al. Personalized therapy algorithms for type 2 diabetes: a phenotype-based approach. Pharmgenomics Pers Med 7 (2014), 129–136.
Ismail-Beigi, F., Moghissi, E., Tiktin, M., Hirsch, I.B., Inzucchi, S.E., Genuth, S., Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 154 (2011), 554–559.
Scheen, A.J., Safety of dipeptidyl peptidase-4 inhibitors for treating type 2 diabetes. Expert Opin Drug Saf 14 (2015), 505–524.
Monami, M., Cremasco, F., Lamanna, C., Marchionni, N., Mannucci, E., Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 27 (2011), 362–372.
McGill, J.B., Vlajnic, A., Knutsen, P.G., Recklein, C., Rimler, M., Fisher, S.J., Effect of gender on treatment outcomes in type 2 diabetes mellitus. Diabetes Res Clin Pract 102 (2013), 167–174.
Scheen, A.J., Paquot, N., Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. Diabetes Metab 39 (2013), 179–190.
Scheen, A.J., Van Gaal, L.F., Combating the dual burden : therapeutic targeting of common pathways in obesity and type 2 diabetes. Lancet Diabetes Endocrinol 2 (2014), 911–922.
Van Gaal, L., Scheen, A., Weight management in type 2 diabetes: current and emerging approaches to treatment. Diabetes Care 38 (2015), 1161–1172.
Williams, L.K., Padhukasahasram, B., Ahmedani, B.K., Peterson, E.L., Wells, K.E., Gonzalez Burchard, E., et al. Differing effects of metformin on glycemic control by race-ethnicity. J Clin Endocrinol Metab 99 (2014), 3160–3168.
Kim, Y.G., Hahn, S., Oh, T.J., Kwak, S.H., Park, K.S., Cho, Y.M., Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis. Diabetologia 56 (2013), 696–708.
Scheen, A.J., Pharmacokinetics and clinical use of incretin-based therapies in patients with chronic kidney disease and type 2 diabetes. Clin Pharmacokinet 54 (2015), 1–21.
Scheen, A.J., Pharmacokinetics, pharmacodynamics and clinical use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and chronic kidney disease. Clin Pharmacokinet 54 (2015), 691–708.
Scheen, A.J., Pharmacokinetic and toxicological considerations for the treatment of diabetes in patients with liver disease. Expert Opin Drug Metab Toxicol 10 (2014), 839–857.
Belfort, R., Harrison, S.A., Brown, K., Darland, C., Finch, J., Hardies, J., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N Engl J Med 355 (2006), 2297–2307.
Armstrong, M.J., Gaunt, P., Aithal, G.P., Barton, D., Hull, D., Parker, R., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (2016), 679–690.
Gilbert, R.E., Krum, H., Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy. Lancet 385 (2015), 2107–2117.
Scheen, A.J., Do thiazolidinediones increase the risk of congestive heart failure and cardiovascular death?. Nature Clin Pract Endocrinol Metab 4 (2008), 260–261.
Zinman, B., Wanner, C., Lachin, J.M., Fitchett, D., Bluhmki, E., Hantel, S., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
Green, J.B., Bethel, M.A., Armstrong, P.W., Buse, J.B., Engel, S.S., Garg, J., et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 373 (2015), 232–242.
Group UKPDS, Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet 352 (1998), 854–865.
Scheen, A.J., Outcomes and lessons from the PROactive study. Diabetes Res Clin Pract 98 (2012), 175–186.
Engelbrechtsen, L., Andersson, E., Roepstorff, S., Hansen, T., Vestergaard, H., Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes. Pharmacogenet Genomics 25 (2015), 475–484.
Scheen, A.J., Castillo, M.J., Lefebvre, P.J., Assessment of residual insulin secretion in diabetic patients using the intravenous glucagon stimulatory test: methodological aspects and clinical applications. Diabetes Metab 22 (1996), 397–406.
Saisho, Y., Importance of beta cell function for the treatment of type 2 diabetes. J Clin Med 3 (2014), 923–943.
Jones, A.G., Hattersley, A.T., The clinical utility of C-peptide measurement in the care of patients with diabetes. Diabet Med 30 (2013), 803–817.
Jones, A.G., McDonald, T.J., Shields, B.M., Hill, A.V., Hyde, C.J., Knight, B.A., et al. Markers of beta-cell failure predict poor glycemic response to GLP-1 receptor agonist therapy in type 2 diabetes. Diabetes Care 39 (2016), 250–257.
Pearson, E., Personalized medicine in diabetes: the role of ’omics’ and biomarkers. Diabet Med, 2016, 10.1111/dme.13075 [Epub ahead of print].
Mamza, J., Mehta, R., Donnelly, R., Idris, I., Determinants of glycemic response to add-on therapy with a dipeptidyl peptidase-4 inhibitor: a retrospective cohort study using a United Kingdom primary care database. Diabetes Technol Ther 18 (2016), 85–92.
Nishimura, T., Meguro, S., Sekioka, R., Tanaka, K., Saisho, Y., Irie, J., et al. C-peptide immunoreactivity index is associated with improvement of HbA1c: 2-Year follow-up of sitagliptin use in patients with type 2 diabetes. Diabetes Res Clin Pract 108 (2015), 441–447.
Nakamura, A., Terauchi, Y., Factors associated with the glucose-lowering effect of vildagliptin identified from the results of the oral glucose tolerance test in Japanese patients with type 2 diabetes. Endocr J 60 (2013), 45–49.
Mooradian, A., Chehade, J.M., Mooradian, A.D., Advantages and pitfalls of antihyperglycemic combination pills as first-line therapy in the management of type 2 diabetes. Am J Ther, 2015 [Epub ahead of print].
Qiu, Y., Li, Q., Tang, J., Fan, C.P., Li, Z., Apecechea, M., et al. Why physicians do not initiate dual therapy as recommended by AACE guidelines: a survey of clinicians in the United States. Diabetes Res Clin Pract 108 (2015), 456–465.
DeFronzo, R.A., Stonehouse, A.H., Han, J., Wintle, M.E., Relationship of baseline HbA1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials. Diabet Med 27 (2010), 309–317.
Rosenstock, J., Hansen, L., Zee, P., Li, Y., Cook, W., Hirshberg, B., et al. Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes Care 38 (2015), 376–383.
Scheen, A.J., Schmitt, H., Jiang, H.H., Ivanyi, T., Individualizing treatment of type 2 diabetes by targeting postprandial or fasting hyperglycaemia: Response to a basal vs a premixed insulin regimen by HbA1c quartiles and ethnicity. Diabetes Metab 41 (2015), 216–222.
Meier, J.J., GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus. Nat Rev Endocrinol 8 (2012), 728–742.
Mannino, G.C., Sesti, G., Individualized therapy for type 2 diabetes: clinical implications of pharmacogenetic data. Mol Diagn Ther 16 (2012), 285–302.
van Leeuwen, N., Swen, J.J., Guchelaar, H.J., t Hart, L.M., The role of pharmacogenetics in drug disposition and response of oral glucose-lowering drugs. Clin Pharmacokinet 52 (2013), 833–854.
Hara, K., Kadowaki, T., Odawara, M., Genes associated with diabetes: potential for novel therapeutic targets?. Expert Opin Ther Targets 20 (2016), 255–267.
Avery, P., Mousa, S.S., Mousa, S.A., Pharmacogenomics in type II diabetes mellitus management: steps toward personalized medicine. Pharmgenomics Pers Med 2 (2009), 79–91.
Semiz, S., Dujic, T., Causevic, A., Pharmacogenetics and personalized treatment of type 2 diabetes. Biochem Med (Zagreb) 23 (2013), 154–171.
Kirchheiner, J., Roots, I., Goldammer, M., Rosenkranz, B., Brockmoller, J., Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet 44 (2005), 1209–1225.
Shu, Y., Sheardown, S.A., Brown, C., Owen, R.P., Zhang, S., Castro, R.A., et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 117 (2007), 1422–1431.
Dujic, T., Zhou, K., Donnelly, L.A., Tavendale, R., Palmer, C.N., Pearson, E.R., Association of organic cation transporter 1 with intolerance to metformin in type 2 diabetes: a GoDARTS study. Diabetes 64 (2015), 1786–1793.
Dujic, T., Causevic, A., Bego, T., Malenica, M., Velija-Asimi, Z., Pearson, E.R., et al. Organic cation transporter 1 variants and gastrointestinal side effects of metformin in patients with type 2 diabetes. Diabet Med 33 (2016), 511–514.
GoDarts, Group UDPS, Wellcome Trust Case Control C, Zhou, K., Bellenguez, C., Spencer, C.C., et al. Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nat Genet 43 (2011), 117–120.
Reitman, M.L., Schadt, E.E., Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117 (2007), 1226–1229.
Scheen, A.J., Personalising metformin therapy: a clinician's perspective. Lancet Diabetes Endocrinol 2 (2014), 442–444.
Shepherd, M., Shields, B., Ellard, S., Rubio-Cabezas, O., Hattersley, A.T., A genetic diagnosis of HNF1A diabetes alters treatment and improves glycaemic control in the majority of insulin-treated patients. Diabet Med 26 (2009), 437–441.
Pearson, E.R., Donnelly, L.A., Kimber, C., Whitley, A., Doney, A.S., McCarthy, M.I., et al. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. Diabetes 56 (2007), 2178–2182.
Holstein, A., Hahn, M., Korner, A., Stumvoll, M., Kovacs, P., TCF7L2 and therapeutic response to sulfonylureas in patients with type 2 diabetes. BMC Med Genet, 12, 2011, 30.
Sesti, G., Marini, M.A., Cardellini, M., Sciacqua, A., Frontoni, S., Andreozzi, F., et al. The Arg972 variant in insulin receptor substrate-1 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes. Diabetes Care 27 (2004), 1394–1398.
Loganadan, N.K., Huri, H.Z., Vethakkan, S.R., Hussein, Z., Genetic markers predicting sulphonylurea treatment outcomes in type 2 diabetes patients: current evidence and challenges for clinical implementation. Pharmacogenomics J, 2016, 10.1038/tpj.2015.95 [Epub ahead of print].
Scheen, A.J., Drug-drug and food-drug pharmacokinetic interactions with new insulinotropic agents repaglinide and nateglinide. Clin Pharmacokinet 46 (2007), 93–108.
Kalliokoski, A., Neuvonen, P.J., Niemi, M., SLCO1B1 polymorphism and oral antidiabetic drugs. Basic Clin Pharmacol Toxicol 107 (2010), 775–781.
Scheen, A.J., Pharmacokinetic interactions with thiazolidinediones. Clin Pharmacokinet 46 (2007), 1–12.
Kawaguchi-Suzuki, M., Frye, R.F., Current clinical evidence on pioglitazone pharmacogenomics. Front Pharmacol, 4, 2013, 147.
Stage, T.B., Christensen, M.M., Feddersen, S., Beck-Nielsen, H., Brosen, K., The role of genetic variants in CYP2C8, LPIN1, PPARGC1A and PPARgamma on the trough steady-state plasma concentrations of rosiglitazone and on glycosylated haemoglobin A1c in type 2 diabetes. Pharmacogenet Genomics 23 (2013), 219–227.
Della-Morte, D., Palmirotta, R., Rehni, A.K., Pastore, D., Capuani, B., Pacifici, F., et al. Pharmacogenomics and pharmacogenetics of thiazolidinediones: role in diabetes and cardiovascular risk factors. Pharmacogenomics 15 (2014), 2063–2082.
Bluher, M., Lubben, G., Paschke, R., Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care 26 (2003), 825–831.
Wang, G., Wang, X., Zhang, Q., Ma, Z., Response to pioglitazone treatment is associated with the lipoprotein lipase S447X variant in subjects with type 2 diabetes mellitus. Int J Clin Pract 61 (2007), 552–557.
Yang, H., Ye, E., Si, G., Chen, L., Cai, L., Ye, C., et al. Adiponectin gene polymorphism rs2241766 T/G is associated with response to pioglitazone treatment in type 2 diabetic patients from southern China. PLoS One, 9, 2014, e112480.
Scheen, A.J., Pharmacokinetics of dipeptidylpeptidase-4 inhibitors. Diabetes Obes Metab 12 (2010), 648–658.
Aquilante, C.L., Wempe, M.F., Sidhom, M.S., Kosmiski, L.A., Predhomme, J.A., Effect of ABCB1 polymorphisms and atorvastatin on sitagliptin pharmacokinetics in healthy volunteers. Eur J Clin Pharmacol 69 (2013), 1401–1409.
Su, H., Boulton, D.W., Barros, A. Jr., Wang, L., Cao, K., Bonacorsi, S.J. Jr, et al. Characterization of the in vitro and in vivo metabolism and disposition and cytochrome P450 inhibition/induction profile of saxagliptin in human. Drug Metab Dispos 40 (2012), 1345–1356.
Zimdahl, H., Ittrich, C., Graefe-Mody, U., Boehm, B.O., Mark, M., Woerle, H.J., et al. Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin. Diabetologia 57 (2014), 1869–1875.
Amblee, A., Patient profiling in diabetes and role of canagliflozin. Pharmgenomics Pers Med 7 (2014), 367–377.
Francke, S., Mamidi, R.N., Solanki, B., Scheers, E., Jadwin, A., Favis, R., et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol 55 (2015), 1061–1072.
Hoeben, E., De Winter, W., Neyens, M., Devineni, D., Vermeulen, A., Dunne, A., Population pharmacokinetic modeling of canagliflozin in healthy volunteers and patients with type 2 diabetes mellitus. Clin Pharmacokinet 55 (2016), 209–223.

Similar publications